Introduction
============

Cerebral microbleeds (CMBs) are defined as hypointense lesions on T2\*-weighted gradient echo images (GRE) caused by previous microhemorrhages \[[@b1-jos-2016-00360]\]. CMBs are regarded as one of the indicators of cerebral small vessel disease \[[@b2-jos-2016-00360],[@b3-jos-2016-00360]\], especially when located in the deep gray matter or infratentorial area \[[@b4-jos-2016-00360]\]. However, CMBs can also be found in lobar (cortical) areas. Risk factors associated with CMBs in the lobar area are different than those associated with deep CMBs \[[@b5-jos-2016-00360],[@b6-jos-2016-00360]\]. A different pathomechanism of cortical microangiopathy by amyloid deposition (i.e., cerebral amyloid angiopathy) is regarded as the major cause of lobar CMB \[[@b5-jos-2016-00360],[@b7-jos-2016-00360]\]. In addition, lobar CMBs are also predominantly observed in patients with a cardioembolic source of septic emboli, which may cause small mycotic aneurysms in their cerebral arteries \[[@b8-jos-2016-00360]\].

The prevalence of CMBs in stroke patients differs according to the subtype of ischemic stroke. The prevalence has been found to be highest in patients with small lacunar infarctions \[[@b9-jos-2016-00360]-[@b11-jos-2016-00360]\]; however, CMBs in other subtypes of stroke are also common \[[@b12-jos-2016-00360],[@b13-jos-2016-00360]\]. In fact, up to one-third of cardioembolic stroke (CE) cases demonstrate CMBs \[[@b14-jos-2016-00360]-[@b16-jos-2016-00360]\]. Considering that patients with CE require long-term anticoagulation, and that anticoagulation increases the risk of intracerebral hemorrhage, especially in patients with multiple CMBs, understanding the pathomechanism of CMBs according to ischemic stroke subtype or location may be important in determining the treatment strategy for secondary stroke prevention.

In our current study, we investigated the risk factors and locations of CMBs in patients with different ischemic stroke subtypes, and the risk factors for CMBs in different locations.

Methods
=======

Patients
--------

Ischemic stroke patients who were admitted within 1 week of stroke onset to the stroke center at Asan Medical Center (Seoul, Korea) between January 2007 and January 2010 were retrospectively reviewed from a prospectively collected database. Among these cases, patients classified as having large artery atherosclerosis (LAA), small vessel occlusion (SVO), or CE were consecutively enrolled after excluding other etiologies. The ischemic stroke subtypes in this population were classified in accordance with the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) system \[[@b17-jos-2016-00360]\]. Electrocardiography was performed in all patients for classification. Holter monitoring, and transthoracic and/or transesophageal echocardiography were performed in selected patients who (1) had a history of heart disease or arrhythmia on electrocardiography, (2) were young (\<50 years of age), or (3) had any cortical lesion on diffusion-weighted image without evidence of the embolic source on magnetic resonance angiography. Patients classified as undetermined or other determined etiology and patients with poor quality image that were not amenable to analysis were excluded from the study. The Institutional Review Board of 00 Medical Center approved this study. The requirement for obtaining informed consent was waived because of the retrospective nature of the analysis.

Clinical data
-------------

The demographic characteristics of the study patients, including their vascular risk factors and previous use of antithrombotic agents (antiplatelet agent and anticoagulants) were collected from medical records. The risk factors included hypertension (defined as receiving medications for hypertension or blood pressure \>140/90 mmHg on repeated measurements), diabetes mellitus (defined as receiving medications for diabetes mellitus, fasting blood sugar ≥126 mg/dL or HbA1c ≥6.5%, or a casual plasma glucose \>200 mg/dL), previous heart disease, hypercholesterolemia (defined as receiving cholesterol-reducing agents or an overnight fasting cholesterol level ≥240 mg/dL, ≥200 mg/dL triglycerides, or Low density lipoprotein (LDL) cholesterol ≥160 mg/dL), and current cigarette smokin \[[@b18-jos-2016-00360]\].

Imaging protocol and analysis
-----------------------------

MRI scans were obtained within one week of stroke onset using either a 1.5 T or 3.0 T MR imaging unit. All the enrolled patients underwent diffusion-weighted image, GRE, and magnetic resonance angiography. The common parameters for diffusion-weighted image were a slice thickness of 5 mm, an inter-slice gap of 2 mm, 20 axial slices, and a field of view of 250 mm. The MRI parameters for GRE were a slice of thickness of 5 mm, an inter-slice gap of 2 mm, 20 axial slices, a field of view of 250 mm, a 400-ms repetition time, 30-ms echo time, 20° flip angle, and a 256×192 matrix. Common magnetic resonance angiography parameters included a flip angle of 20°, a 512×512 matrix, and a field of view of 250 mm.

CMBs were defined as lesions with homogeneous round signal loss and a diameter ≤5 mm on GRE \[[@b9-jos-2016-00360]\]. However, hypointense lesions within the subarachnoid space and areas of symmetrical hypointensity in the globus pallidus on GRE were considered likely to represent adjacent pial blood vessels and calcifications, respectively \[[@b9-jos-2016-00360]\]. The locations of the CMBs were classified as lobar, deep, or diffuse. CMBs located at the cortico-subcortical area of each lobe (i.e., frontal, parietal, temporal, or occipital) were regarded as lobar CMBs. CMBs in the basal ganglia, thalamus, brainstem, and cerebellum were categorized as deep CMBs. Multiple CMBs that were distributed throughout both the lobar and deep areas were defined as diffuse CMBs. If at least one CMB existed at lobar area or deep area, the patient was regarded to have any lobar or any deep CMB. The number of CMBs was counted separately in each area. Classification of stroke subtype and detection of the CMBs were performed by two independent neurologists (Y.Y and H.S) who were blind to the clinical data, and any discrepancies were reevaluated at a consensus meeting.

Data analysis
-------------

The CMB prevalence was compared between patients with different stroke subtypes. The risk factors for CMBs were also compared. Pearson chi-square test, student t test, or Mann-Whitney test was appropriately used. In addition, multivariable logistic regression analysis was performed to estimate the independent contributions of various factors on the presence of CMBs in different stroke subtypes and locations. Variables were selected for entry into the model based on the results of univariable analysis (*P*≤0.2); SVO group: age, hypertension and previous stroke history, LAA group: hypertension and previous stroke history, CE group: hypertension and previous use of antithrombotic agents were entered. For locations, factors associated with any lobar, lobar, any deep and deep CMBs were investigated. The odds ratio (OR) and 95% confidence interval were also determined. The concordance rates between the two investigators were evaluated. A 2-tailed *P* value \<0.05 was considered statistically significant. SPSS for Windows was used for these analyses (version 18.0; SPSS Inc., Chicago, IL, USA).

Results
=======

Study population
----------------

During the study period, 1,357 patients within 7 days from ischemic stroke onset were registered to the database during the study period. Among them, 169 patients with undetermined etiology and 64 patients with other determined etiology were excluded. Of them, 1,124 patients were initially determined to be eligible to participate and were screened. However, 91 patients were excluded due to suboptimal image quality and a final study population of 1,033 patients was included. The ischemic stroke subtypes were LAA (n=432; 41.8%), SVO (n=304; 29.4%), and CE (n=297; 28.8%; [Figure 1](#f1-jos-2016-00360){ref-type="fig"}). The demographic features and vascular risk factors were significantly different between patients with different ischemic stroke subtypes.

Compared with LAA or SVO patients, the CE cases were significantly more likely to be elderly. Most of the vascular risk factors, including hypertension, diabetes mellitus, hyperlipidemia, and smoking, were less frequent in CE patients. However, the proportion of CE patients who had previously used antithrombotic agents was significantly higher than the other subtypes ([Table 1](#t1-jos-2016-00360){ref-type="table"}).

Distribution of CMB
-------------------

The prevalence and mean number of CMBs were significantly different between the various ischemic stroke subtypes: prevalence, SVO (40.5%), CE (33.0%), and LAA (24.8%; *P*\<0.001; [Table 1](#t1-jos-2016-00360){ref-type="table"}); mean number of CMBs, SVO (mean±Standard deviation: 4.65±7.40), CE (3.09±3.49), and LAA (3.12±3.63; *P*=0.041). As indicated in [Table 1](#t1-jos-2016-00360){ref-type="table"} and [Figure 1](#f1-jos-2016-00360){ref-type="fig"}, the location of the CMBs also differed according to the subtype of ischemic stroke (*P*=0.004). The presence of any lobar CMB was high in SVO and CE patients, whereas deep CMB was frequently observed from SVO patients ([Figure 2](#f2-jos-2016-00360){ref-type="fig"}). Finally, the ratio of patients with any CMBs in the lobar area to that of deep area was relatively high in patients with CE (63/71; 88.7%) compared to SVO (71/97; 73.2%) or LAA (43/85; 50.6%) cases ([Figure 2](#f2-jos-2016-00360){ref-type="fig"}). The concordance rate between the two investigators for the location of CMBs was 90.4%, and the kappa value was 0.71.

Risk factors associated with CMB in each subtypes
-------------------------------------------------

The clinical characteristics of patients with and without CMB for each ischemic stroke subtype are presented in [Table 2](#t2-jos-2016-00360){ref-type="table"}. In patients categorized as SVO or LAA, the prevalence of hypertension and previous stroke history were higher in patients with CMBs than in those without. Patients with CMBs were older (66.0±11.0 vs. 63.1±13.0; *P*\<0.05) than those without CMBs in the SVO group. By multivariate analysis, hypertension (OR=1.956 \[95% confidence interval=1.064--3.594\]; *P*=0.031) and a previous history of stroke (OR=1.929 \[1.125--3.309\]; *P*=0.017) were independent risk factors for CMBs in SVO patients. Similarly, hypertension (OR=3.656 \[1.760--7.594\]; *P*=0.001) and a previous history of stroke (OR=1.663 \[1.036--2.669\] *P*=0.035) were also independent risk factors for CMBs in LAA patients. However, these factors were not associated with the presence of CMBs in CE patients.

Risk factors of CMB according to location
-----------------------------------------

In terms of CMB location, the results of univariable analysis are demonstrated at [Table 3](#t3-jos-2016-00360){ref-type="table"}. According to the results of multivariable analysis, the presence of strictly lobar CMB was independently associated with CE (OR=1.85 \[1.02--3.34\]; *P*=0.042) and use of antithrombotic agents (OR=1.80 \[1.10--2.94\]; *P*=0.019). Age (OR=1.02 \[1.00--1.04\]; *P*=0.015) and hypertension (OR=1.61 \[1.08--2.40\]; *P*=0.020) were independently associated with the presence of deep CMB. The presence of any lobar CMB was independently associated with the use of antithrombotic agents (OR=1.97 \[1.26--3.07\]; *P*=0.003), whereas sex was the only factor associated with the presence of any deep CMB (male sex: OR=0.50 \[0.29--0.86\]; *P*=0.013).

Discussion
==========

Our present findings indicate that the prevalence, location, and risk factors associated with CMBs differ significantly according to ischemic stroke subtype. CMBs were most frequently observed in SVO patients, followed by CE and LAA patients. The distribution of CMBs was mostly in deep areas in SVO and LAA patients, whereas the CMBs were found in the lobar area relatively more frequently in CE patients compared to SVO and LAA patients. The presence of CMBs was associated with hypertension and previous stroke history in SVO or LAA cases, whereas there was no significant association between those factors and the presence of CMBs in patients with CE. Prior use of antithrombotics was associated with the presence of any lobar CMB, which was relatively frequent in CE patients.

The prevalence of CMB according to ischemic stroke subtype in our current series was consistent with the findings of previous reports. Not only the prevalence, but also the CMB location, differed according to ischemic stroke subtype. SVO patients more frequently demonstrated CMBs in deep areas, where the deep perforating arteries exist \[[@b19-jos-2016-00360],[@b20-jos-2016-00360]\]. Previously, CMBs located in deep areas were found to be associated with high blood pressure, renal impairment, and heavy alcohol consumption \[[@b21-jos-2016-00360]-[@b23-jos-2016-00360]\]. From our present study findings, CMBs in SVO patients were associated with hypertension and a previous history of stroke. CMBs in those areas are suggested to be caused by hypertensive arteriopathy, which affects the perforators \[[@b24-jos-2016-00360]\].

CMBs in lobar areas have been associated with smoking, APOE ε4, and low cholesterol levels \[[@b5-jos-2016-00360],[@b22-jos-2016-00360]\]. Lobar CMBs are also regarded as an imaging biomarker for cerebral amyloid angiopathy \[[@b25-jos-2016-00360]\]. Recently, several studies revealed lobar CMBs in specific lobar areas to be associated with various degenerative diseases (e.g. Alzheimer's disease, Parkinson's disease and Diffuse Lewy body disease) \[[@b26-jos-2016-00360]-[@b28-jos-2016-00360]\]. However, age, which is the strongest risk factor for degenerative diseases, was not found to be associated with lobar CMBs in our present study with stroke population. Instead, we found that CE and the previous use of antithrombotics were associated with the presence of lobar CMB.

CMBs have previously been associated with the use of anticoagulants, and this relationship was reported to be stronger in patients from the general population with a greater fluctuation of prothrombin time \[[@b29-jos-2016-00360]\]. Furthermore, among patients with ischemic stroke, CMBs were found to be common in patients with atrial fibrillation, and the use of antithrombotics was independently associated with the presence of lobar but not deep CMBs \[[@b13-jos-2016-00360]\]. In our present study, lobar CMBs were more frequent in CE patients, and the presence of lobar CMB was associated with a prior use of antithrombotics. Patients with CE generally show small asymptomatic cortical infarctions, higher spontaneous recanalization rates, and concomitant hemorrhagic transformations \[[@b30-jos-2016-00360],[@b31-jos-2016-00360]\]. Considering that patients under oral anticoagulation are more likely to develop CMBs, the use of antithrombotics may enhance micro-hemorrhages occurring as a result of recanalization of small arterioles obstructed by an asymptomatic embolus originating from the heart \[[@b32-jos-2016-00360]-[@b34-jos-2016-00360]\]. The characteristics of lobar CMBs developed through such a mechanism may differ from CMBs caused by degenerative disease.

Our study has a number of limitations of note. First, due to its retrospective design, there was a risk of selection bias, which could have impacted on our findings of cause and effect. However, our patients were consecutively recruited from a single center, and most of these cases underwent brain MRI using an established protocol. Second, we used both 1.5 T and 3.0 T MRI, although 1.5 T MRI is inferior for the detection of CMBs \[[@b35-jos-2016-00360]\]. Thus, the prevalence of CMBs may have been underestimated. Furthermore, we used 5 mm as the maximum diameter for defining CMB. This may also have influenced the prevalence of CMBs to be underestimated.

Conclusions
===========

Notwithstanding the above limitations, our present study demonstrated that the distribution and risk factors associated with CMBs differed by stroke subtype, especially in patients with CE compared with SVO or LAA. Our results suggest different pathogenic mechanisms for the development of CMBs of each subtype and that the previous use of antithrombotic agents is related to CMB location.
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###### 

Baseline characteristics of the study population

                                               Cardioembolism (n=297)   Small vessel occlusion (n=304)   Large artery atherosclerosis (n=432)   *P*
  -------------------------------------------- ------------------------ -------------------------------- -------------------------------------- ----------
  Male                                         160 (53.9)               180 (59.2)                       283 (65.5)                             0.006
  Age (year)                                   70.0 \[10.3\]            64.4 \[12.3\]                    65.1 \[11.2\]                          \< 0.001
  Hypertension                                 208 (70.0)               236 (77.6)                       336 (77.8)                             0.034
  Diabetes Mellitus                            67 (22.6)                103 (33.9)                       164 (38.0)                             \< 0.001
  Hyperlipidemia                               80 (26.9)                185 (60.9)                       244 (56.5)                             \< 0.001
  Coronary artery disease                      32 (10.8)                15 (4.9)                         43 (10.0)                              0.019
  Current smoking                              104 (35.0)               132 (43.4)                       203 (47.0)                             0.005
  Previous stroke history                      63 (21.2)                75 (24.7)                        121 (28.0)                             0.113
  Previous use of antithrombotic medication    176 (59.3)               87 (28.6)                        161 (37.3)                             \< 0.001
   Antiplatelet agent                          111 (37.4)               87 (28.6)                        159 (36.8)                             
   Anticoagulants                              65 (21.9)                0                                2 (0.5)                                
  The presence of cerebral microbleeds (CMB)   98 (33.0)                123 (40.5)                       107 (24.8)                             \< 0.001
  Presence of any lobar CMB                    63 (21.2)                71 (23.4)                        43 (10.0)                              \< 0.001
  Presence of any deep CMB                     71 (23.9)                97 (31.9)                        85 (19.7)                              0.001
  Location of CMB                                                                                                                               0.004
   Lobar                                       27 (9.1)                 26 (8.6)                         22 (5.1)                               
   Deep                                        35 (11.8)                52 (17.1)                        64 (14.8)                              
   Diffuse                                     36 (12.1)                45 (14.8)                        21 (4.9)                               
  Mean number of CMB                           3.09 \[3.49\]            4.65 \[7.40\]                    3.12 \[3.63\]                          0.041

Results are expressed as a number (%) or mean \[SD\].

###### 

Risk factors in patients with and without cerebral microbleeds (CMBs) based on stroke subtype

                            Cardioembolism (n=297)   Small vessel occlusion (n=304)   Large artery atherosclerosis (n=432)                                                                                  
  ------------------------- ------------------------ -------------------------------- -------------------------------------- --------------------------------------------------------------- -------------- ------------------------------------------------------------
  Male                      47 (48.0)                113 (56.8)                       73 (59.3)                              107 (59.1)                                                      66 (61.7)      217 (66.8)
  Age (year)                70.6 \[10.4\]            69.7 \[10.3\]                    66.0 \[11.0\]                          63.1 \[13.0\]^[‡](#tfn2-jos-2016-00360){ref-type="table-fn"}^   66.7 \[9.5\]   64.6 \[11.7\]
  Hypertension              74 (75.5)                134 (67.3)                       105 (85.4)                             131 (72.4)^[‡](#tfn2-jos-2016-00360){ref-type="table-fn"}^      98 (91.6)      238 (73.2)^[†](#tfn1-jos-2016-00360){ref-type="table-fn"}^
  Diabetes Mellitus         18 (18.4)                49 (24.6)                        35 (28.5)                              68 (37.6)                                                       33 (30.8)      131 (40.3)
  Hyperlipidemia            29 (29.6)                51 (25.6)                        72 (58.5)                              113 (62.4)                                                      67 (62.6)      177 (54.5)
  Coronary artery disease   11 (11.2)                21 (10.6)                        5 (4.1)                                10 (5.5)                                                        10 (9.3)       33 (10.2)
  Current smoking           36 (36.7)                68 (34.2)                        50 (40.7)                              82 (45.3)                                                       47 (43.9)      156 (48.0)
  Previous stroke history   20 (20.4)                43 (21.6)                        41 (33.3)                              34 (18.8)^[†](#tfn1-jos-2016-00360){ref-type="table-fn"}^       41 (38.3)      80 (24.9)^[‡](#tfn2-jos-2016-00360){ref-type="table-fn"}^
  Use of Antithrombotics    66 (67.3)                110 (55.3)                       39 (31.7)                              48 (26.5)                                                       48 (44.9)      113 (34.8)
  Antiplatelet agent        43 (43.9)                68 (34.2)                        39 (31.7)                              48 (26.5)                                                       46 (43.0)      113 (34.8)
  Anticoagulants            23 (23.5)                42 (21.1)                        0 (0.0)                                0 (0.0)                                                         2 (1.9)        0 (0.0)

Results are expressed as a number (%) or mean \[SD\].

*P*\<0.005;

*P*\<0.05.

###### 

Factors associated with the presence of lobar or deep cerebral microbleeds (CMBs)

                                  Lobar CMB          Any Lobar CMB   Deep CMB           Any Deep CMB                                                 
  ------------------------------- ------------------ --------------- ------------------ -------------- ------------------ ------- ------------------ ----------
  Male                            1.03 (0.79-1.47)   0.762           1.21 (0.78-1.87)   0.401          0.82 (0.58-1.17)   0.275   0.50 (0.29-0.86)   0.013
  Age                             1.01 (0.99-1.04)   0.235           1.02 (1.00-1.04)   0.041          1.02 (1.00-1.04)   0.013   1.00 (0.96-1.01)   0.327
  Hypertension                    1.14 (0.68-1.91)   0.615           1.08 (0.59-1.96)   0.809          1.53 (1.03-2.28)   0.035   0.84 (0.42-1.68)   0.628
  Diabetes mellitus               0.99 (0.59-1.65    0.955           1.20 (0.73-1.96)   0.468          0.65 (0.43-1.01)   0.053   1.13 (0.63-2.00)   0.690
  Hyperlipidemia                  1.26 (0.77-1.70)   0.312           0.76 (0.49-1.17)   0.213          1.10 (0.78-1.55)   0.607   1.18 (0.71-1.98)   0.526
  Coronary artery disease         0.92 (0.45-1.89)   0.814           0.73 (0.33-1.63)   0.445          1.04 (0.62-1.73)   0.883   0.99 (0.38-2.56)   0.979
  Smoking                         1.15 (0.78-1.45)   0.672           1.00 (0.64-1.55)   0.993          1.02 (0.71-1.46)   0.909   1.12 (0.66-1.89)   0.671
  Previous stroke history         1.08 (0.62-1.87)   0.789           1.16 (0.73-1.86)   0.538          1.64 (1.33-1.81)   0.021   1.11 (0.63-1.96)   0.707
  Ischemic stroke subtypes                                                                                                                           
   Large artery atherosclerosis   1                                  1                                 1                          1                  
   Small vessel occlusion         1.74 (0.97-3.14)   0.064           1.75 (1.33-2.16)   0.008          1.19 (0.80-1.77)   0.401   1.91 (1.36-2.68)   \< 0.001
   Cardioembolism                 1.86 (1.04-3.34)   0.037           2.44 (1.60-3.71)   \< 0.001       0.77 (0.49-1.19)   0.242   1.28 (0.90-1.83)   0.174
  Use of Antithrombotic agents    1.81(1.13-2.90)    0.014           1.97 (1.26-3.07)   0.003          1.12 (0.76-1.64)   0.712   0.93 (0.56-1.57)   0.793

OR, odds ratio; CI, confidence interval.
